55 % Overall Response Rate on the safety extension cohorts of the ISO-CC-005 Phase I/IIa study
GOTHENBURG, Sweden, September 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today provided an […]
English
Strengthened patent protection for arfolitixorin in Japan
GOTHENBURG, Sweden, September 1, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), has announced today
Invitation to a conference call and webcast by Isofol in connection with the entered license agreement with Solasia
GOTHENBURG, Sweden, August 13, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) has today
Isofol enters licensing agreement with Solasia to develop and commercialize arfolitixorin in Japan
GOTHENBURG, Sweden, August 13, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) today announced
Isofol’s CEO Ulf Jungnelius has subscribed for all warrants
GOTHENBURG, Sweden, August 4, 2020 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq First North Premier Growth Market: ISOFOL), today announced that
A milestone is reached with the inclusion of 330 patients in the AGENT-study – opening up for the interim analysis
GOTHENBURG, Sweden, July 21, 2020 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq First North Premier Growth Market: ISOFOL), today announced that
AGENT study update with regards to COVID-19
GOTHENBURG, Sweden, July 10, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL), informs that the
Isofol’s rights issue oversubscribed
GOTHENBURG, Sweden, June 3, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the
Consortium of investors acquires subscription rights from Isofol´s founder Professor Bengt Gustavsson
GOTHENBURG, Sweden, May 29, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the
Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million
GOTHENBURG, Sweden, May 14, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the